Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
New combination therapy can help improve cure rates for neuroblastoma

New combination therapy can help improve cure rates for neuroblastoma

No benefits to polychemotherapy after surgery in gastric cancer

No benefits to polychemotherapy after surgery in gastric cancer

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Prodigy Generics launches injectable irinotecan

Prodigy Generics launches injectable irinotecan

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

First study to evaluate treatment based on molecular profiling of advanced pancreatic cancer

First study to evaluate treatment based on molecular profiling of advanced pancreatic cancer

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Researchers identify mechanism with which cancer cells protect themselves against damage

Researchers identify mechanism with which cancer cells protect themselves against damage

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

New way to awaken paternal Ube3a allele linked with Angelman syndrome

New way to awaken paternal Ube3a allele linked with Angelman syndrome

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen receives EC approval to extend therapeutic indications for Vectibix

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Merrimack receives FDA orphan drug status for MM-398 to treat pancreatic cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer